Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction

    Summary
    EudraCT number
    2017-004149-26
    Trial protocol
    DE  
    Global end of trial date
    28 Feb 2025

    Results information
    Results version number
    v1(current)
    This version publication date
    17 Apr 2025
    First version publication date
    17 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    METRIS-HF(EMPA)
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Charité - Universitätsmedizin Berlin
    Sponsor organisation address
    Charitéplatz 1, Berlin, Germany, 10117
    Public contact
    Prof. Dr. Wolfram Döhner, Deutsches Herzzentrum der Charité (DHZC) Klinik für Kardiologie, Angiologie & Intensivmedizin, 49 30450553507, wolfram.doehner@charite.de
    Scientific contact
    Prof. Dr. Wolfram Döhner, Deutsches Herzzentrum der Charité (DHZC) Klinik für Kardiologie, Angiologie & Intensivmedizin , 49 30450553507, wolfram.doehner@charite.de
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Mar 2025
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Feb 2025
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Feb 2025
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Improvement of myocardial contractility and functional capacity in patients with reduced EF (HFrEF and HFmrEF) and insulin resistance in comparison with two control groups (empaglifozin and placebo).
    Protection of trial subjects
    Following the principles of Good Clinical Practice and according to international (European) and German law the sponsor established a system to detect any safety signal and to take appropriate measures to protect patient’s safety. An immediate reaction to any risk given by the drug or the conduct of the trial is guaranteed.
    Background therapy
    Heart failure (HF) is a major clinical burden in modern society and further growing in prevalence, incidence and in health care costs. Diabetes mellitus (DM) is a common comorbidity of HF with mutual aggravation of both diseases and is a risk factor for advanced symptomatic status and further impaired prognosis of HF. Based on the newly emerging clinical evidence on SGLT2- inhibitor treatment in patients with heart failure, there is an urgent need for a better understanding of the underlying mechanisms. The trial design of the METRIS-HF (EMPA) trial offered a unique opportunity to investigate on a mechanistic level the effects of Empagliflozin not only in comparison to placebo but in direct comparison to Metformin which was until now considered first line therapy in patients with HF and diabetes mellitus but may likely be replaced by SGLT2-inhibitors.
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Oct 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 88
    Worldwide total number of subjects
    88
    EEA total number of subjects
    88
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    29
    From 65 to 84 years
    53
    85 years and over
    6

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    153 patients were screened in 2 Charité sites and a further site in Berlin (Unfallkrankenhaus Berlin Marzahn) in Germany according the including criteria of whom 95 were randomized. Furthermore 7 patients were discontinued after treatment arm assignment. 88 patients fulfilled the criteria of being randomized and received the IMP.

    Pre-assignment
    Screening details
    All baseline study-related examinations will be performed within two weeks of randomization.

    Period 1
    Period 1 title
    overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Metformin 500 mg
    Arm description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d
    Arm type
    Experimental

    Investigational medicinal product name
    Metformine
    Investigational medicinal product code
    SUB172801
    Other name
    METFORMIN HYDROCHLORIDE PH. EUR., Sifor 1000
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2x 500mg/d for the first 2 weeks, afterwards up-titrated to 2x1000mg/d (if applicable) plus 1 placebo tablet of Empagliflozin

    Arm title
    Empagliflozin 10 mg
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    EMPAGLIFLOZIN
    Investigational medicinal product code
    SUB35915
    Other name
    Jardiance Filmtabletten (10 mg)
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1x10mg/d plus 2x ½ placebo tablet of Metformin for the first 2 weeks, afterwards 2x 1 placebo tablet of Metformin

    Arm title
    Placebo
    Arm description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    1 placebo tablet of Empagliflozin plus 2x ½ placebo tablet of Metformin for the first 2 weeks, afterwards 2x 1 placebo tablet of Metformin

    Number of subjects in period 1
    Metformin 500 mg Empagliflozin 10 mg Placebo
    Started
    33
    18
    37
    Completed
    33
    18
    37

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Metformin 500 mg
    Reporting group description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d

    Reporting group title
    Empagliflozin 10 mg
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d

    Reporting group values
    Metformin 500 mg Empagliflozin 10 mg Placebo Total
    Number of subjects
    33 18 37 88
    Age categorical
    Units: Subjects
        In utero
    0 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0 0
        Newborns (0-27 days)
    0 0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0 0
        Children (2-11 years)
    0 0 0 0
        Adolescents (12-17 years)
    0 0 0 0
        Adults (18-64 years)
    23 11 19 53
        From 65-84 years
    9 6 14 29
        85 years and over
    1 1 4 6
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    72.18 ( 9.28 ) 67.27 ( 10.33 ) 68.27 ( 11.92 ) -
    Gender categorical
    Units: Subjects
        Female
    7 5 6 18
        Male
    26 13 31 70

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Metformin 500 mg
    Reporting group description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d

    Reporting group title
    Empagliflozin 10 mg
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    Before authorization of the amendment version 3.1 submitted on 02.12.2020 eligible patients were randomized (1:1) to receive active treatment or matching placebo on top of usual care. A titration step (14 days: 500mg bd) was followed by full dose (1000mg bd) for a total treatment period of 24 weeks. Titration was performed for patients with a GFR > 44 ml/min/1.73m2 only. Patients with a GFR between 30 and 44 ml/min, received a dose of 500 mg metformin b.i.d

    Primary: change LV global longitudinal strain (GLS

    Close Top of page
    End point title
    change LV global longitudinal strain (GLS [1]
    End point description
    LV global longitudinal strain (GLS) will be analysed by means of Gaussian linear model for repeated measures (so-called MMRM) with treatment group (Group A vs. Group B vs. Group C), time (week 12, week24). The error terms are assumed to follow a multivariate normal distribution with unstructured covariance. Since the primary endpoint will be assessed by echocardiography for patients not eligible for cardiac MRI, the analyses will be carried out stratified by assessement method (echocardiography and cardiac MRI) and combined in a fixed effect meta-analysis of standardized treatment effects. A one-sided p-value smaller than 2.5% will be considered statistically significant.
    End point type
    Primary
    End point timeframe
    week 24
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The statistical analysis has not yet been finalised. The results will be uploaded as soon as they are available.
    End point values
    Metformin 500 mg Empagliflozin 10 mg Placebo
    Number of subjects analysed
    33
    18
    37
    Units: Prozent (%)
        median (confidence interval 95%)
    0 (0 to 0)
    0 (0 to 0)
    0 (0 to 0)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    overall trial, 24 weeks
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    CTCAE
    Dictionary version
    4.3
    Reporting groups
    Reporting group title
    Metformin
    Reporting group description
    -

    Reporting group title
    Empagliflozin
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    -

    Serious adverse events
    Metformin Empagliflozin Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    10 / 33 (30.30%)
    3 / 18 (16.67%)
    10 / 37 (27.03%)
         number of deaths (all causes)
    2
    0
    3
         number of deaths resulting from adverse events
    0
    0
    2
    Injury, poisoning and procedural complications
    Macrohaematuria
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    heart failure (cardiac decompensation)
         subjects affected / exposed
    2 / 33 (6.06%)
    1 / 18 (5.56%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    0 / 33 (0.00%)
    1 / 18 (5.56%)
    2 / 37 (5.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction/ NSTEMI
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    3 / 37 (8.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    Atrial flutter
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    cardiac chest pain (Angina pectoris)
         subjects affected / exposed
    0 / 33 (0.00%)
    1 / 18 (5.56%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Surgical and medical procedures - Other - Elective cardiac catheterisation
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures - Other - Primary prophylactic implantation of a defilibrator
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    change implanted device to Phrenic nerve stimulation
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Ischemia/stroke
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Synkope
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Multi-organ failure
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    Death NOS
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Immune system disorders
    Anaphylaxis
         subjects affected / exposed
    0 / 33 (0.00%)
    1 / 18 (5.56%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Glaucoma
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Gastroesophageal reflux disease
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    2 / 37 (5.41%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthritis rheumatoide
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    sepsis, pneumogene
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Covid-19-Infektion
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Metformin Empagliflozin Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    17 / 33 (51.52%)
    12 / 18 (66.67%)
    15 / 37 (40.54%)
    Injury, poisoning and procedural complications
    Fracture
    Additional description: ribs fracture/tibia head fracture/fibula fracture
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    2 / 37 (5.41%)
         occurrences all number
    0
    0
    3
    Cardiac disorders
    cardiac chest pain
    Additional description: Angina pectoris
         subjects affected / exposed
    1 / 33 (3.03%)
    1 / 18 (5.56%)
    1 / 37 (2.70%)
         occurrences all number
    1
    1
    1
    Exercise-induced dyspnea
         subjects affected / exposed
    0 / 33 (0.00%)
    2 / 18 (11.11%)
    1 / 37 (2.70%)
         occurrences all number
    0
    2
    1
    Ventricular tachycardia
         subjects affected / exposed
    0 / 33 (0.00%)
    1 / 18 (5.56%)
    2 / 37 (5.41%)
         occurrences all number
    0
    1
    2
    General disorders and administration site conditions
    Flu like symtoms
         subjects affected / exposed
    1 / 33 (3.03%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    1
    0
    1
    Injection site reaction
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1
    Gastrointestinal disorders
    Diarrhea
         subjects affected / exposed
    10 / 33 (30.30%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences all number
    22
    0
    0
    Nausea, Vomiting
         subjects affected / exposed
    2 / 33 (6.06%)
    0 / 18 (0.00%)
    0 / 37 (0.00%)
         occurrences all number
    2
    0
    0
    Constipation
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1
    Renal and urinary disorders
    acute kidney injury
         subjects affected / exposed
    0 / 33 (0.00%)
    1 / 18 (5.56%)
    1 / 37 (2.70%)
         occurrences all number
    0
    1
    1
    Cystitis noninfective
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1
    Psychiatric disorders
    Depression
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Arthritis
         subjects affected / exposed
    1 / 33 (3.03%)
    1 / 18 (5.56%)
    0 / 37 (0.00%)
         occurrences all number
    1
    1
    0
    Pain in extremity
         subjects affected / exposed
    1 / 33 (3.03%)
    1 / 18 (5.56%)
    0 / 37 (0.00%)
         occurrences all number
    1
    1
    0
    back pain
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1
    Infections and infestations
    Covid- 19- Infektion
         subjects affected / exposed
    2 / 33 (6.06%)
    5 / 18 (27.78%)
    1 / 37 (2.70%)
         occurrences all number
    2
    5
    1
    upper respiratory infections
         subjects affected / exposed
    0 / 33 (0.00%)
    2 / 18 (11.11%)
    0 / 37 (0.00%)
         occurrences all number
    0
    3
    0
    Herpes simplex reactivation
         subjects affected / exposed
    0 / 33 (0.00%)
    0 / 18 (0.00%)
    1 / 37 (2.70%)
         occurrences all number
    0
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    10 Dec 2020
    - add a new arm as active comparator "Empagliflozin" - change the sponsor code from Metris-HF to Metris-HF (EMPA) - update protocol Version 3.1 (02/12/2020)
    09 Feb 2021
    - Label for study IMP have been modified
    06 Feb 2023
    - Extension of the study period until March 2024 -update protocol Version 3.2 (20/01/2023)

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 01:59:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA